A
1.37
-0.02 (-1.44%)
| Previous Close | 1.39 |
| Open | 1.39 |
| Volume | 2,567,946 |
| Avg. Volume (3M) | 4,019,909 |
| Market Cap | 364,616,288 |
| Price / Sales | 7.11 |
| Price / Book | 1.37 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Operating Margin (TTM) | -726.31% |
| Diluted EPS (TTM) | -0.880 |
| Quarterly Revenue Growth (YOY) | -11.00% |
| Total Debt/Equity (MRQ) | 83.84% |
| Current Ratio (MRQ) | 9.24 |
| Operating Cash Flow (TTM) | -241.32 M |
| Levered Free Cash Flow (TTM) | -214.39 M |
| Return on Assets (TTM) | -20.27% |
| Return on Equity (TTM) | -49.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Autolus Therapeutics plc | Bullish | Mixed |
AIStockmoo Score
1.0
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 18.09% |
| % Held by Institutions | 90.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mak Capital One Llc | 30 Sep 2025 | 26,017,616 |
| Syncona Portfolio Ltd | 30 Sep 2025 | 16,640,720 |
| Tfg Asset Management Gp Ltd | 30 Sep 2025 | 9,500,000 |
| Schroder Investment Management Group | 30 Sep 2025 | 8,433,253 |
| Axa Investment Managers S.A. | 30 Sep 2025 | 3,361,156 |
| Laurion Capital Management Lp | 30 Sep 2025 | 3,316,626 |
| 52 Weeks Range | ||
| Median | 10.00 (629.93%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 03 Nov 2025 | 10.00 (629.93%) | Buy | 1.56 |
| 20 Oct 2025 | 10.00 (629.93%) | Buy | 1.70 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |